Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Imbruvica Ibrutinib Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Reimburse with clinical criteria and/or conditions Complete
Imbruvica Ibrutinib Chronic Lymphocytic Leukemia (previously untreated) Reimburse with clinical criteria and/or conditions Complete
Imbruvica Ibrutinib Waldenstrom's Macroglobulinemia Do not reimburse Complete
Imbruvica Ibrutinib Mantle Cell Lymphoma (relapsed/refractory) Reimburse with clinical criteria and/or conditions Complete
Imbruvica ibrutinib Leukemia Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Imbruvica ibrutinib Leukemia Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Imbruvica ibrutinib Waldenström’s Macroglobulinemia Reimburse with clinical criteria and/or conditions Complete
Imcivree setmelanotide Bardet-Biedl syndrome Reimburse with clinical criteria and/or conditions Complete
Imdelltra tarlatamab Extensive stage small cell lung cancer Active
Imfinzi durvalumab Extensive-stage small cell lung cancer Reimburse with clinical criteria and/or conditions Complete